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This issue of Current Oncology cuts a broad swath
through highly topical subjects in cancer biology and
cancer care. An article by Chasen and Dippenaar ad-
dresses the ever-increasing emphasis on dealing with
cancer as a systemic disease, showing how to assure
optimal care, the patient’s condition must be addressed
in a multidisciplinary fashion, including dealing with
nutritional concerns, rehabilitation, and psychic distress.
Batist and Shinder give a fascinating description
of the growth—and changes—in the McGill Univer-
sity Department of Oncology since the start of the
1990s. They note how the functional alterations during
the time since have largely been driven by the evolu-
tion of knowledge in the field of oncology.
Two papers address aspects of gynecologic can-
cer. Nayot et al. describe a pilot study indicating that
preoperative positron-emission tomography with com-
puted tomography does not necessarily predict lymph
node status in endometrial cancer. Then Gien and as-
sociates present evidence that hormonal therapy may
be of no value as adjuvant treatment for patients with
stage I endometrial cancer.
Two articles consider differing aspects of targeted
biopharmaceutical—or perhaps “bioceutical”—therapy.
Examining the cost burden of trastuzumab and
bevacizumab (two monoclonal antibodies) as therapy
for solid tumours in Canada, Drucker et al. effectively
raise the question, “When we finally have a variety of
cures for various cancers requiring this form of targeted
therapy, will Canada’s publicly funded health care sys-
tem be able to afford them?” In the same domain, but
with a different spin, Trinkaus and colleagues report on
a patient with drug-induced immune thrombocytopenia
secondary to sunitinib, a specific inhibitor of a tyrosine
kinase. Theirs is the first such report in the literature.
In an international submission, Amouzegar–
Hashemi et al. show that the outcomes for single as
compared with multiple fractions of palliative radio-
therapy for bone metastases in Iranian patients are
similar to those reported elsewhere in the literature.
And finally, Current Oncology is pleased to present a
series of abstracts from the Ontario Thoracic Cancer
Conference that provide significant additions to knowl-
edge in this area of activity.
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